Efficacy, Safety and Neural Mechanism of Stellate Ganglion Block in the Treatment of Anxiety. Disorder.

Launched by NANJING MEDICAL UNIVERSITY · Aug 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Stellate Ganglion Block (SGB) to see if it can help people with anxiety disorders. SGB is a procedure that uses ultrasound to deliver medication to a specific nerve area in the neck, aiming to reduce anxiety symptoms. Researchers want to find out if this treatment is safe, how well it works, and how it affects the nervous system and certain brain areas involved in anxiety. They will measure the changes in anxiety levels and monitor heart health to understand how SGB impacts the body.

To participate in this study, individuals should be between 18 and 60 years old and have been diagnosed with an anxiety disorder. Participants will need to be right-handed and willing to sign a consent form. Those with serious physical or mental health issues, suicidal thoughts, or who are pregnant or breastfeeding cannot join. If eligible, participants can expect to receive the SGB treatment, and they will be monitored closely to assess their progress and any effects on their anxiety symptoms. This study is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18-60 years old
• • 2. Diagnosed with various types of anxiety disorders according to the DSM-5, and meet the diagnostic criteria for pain disorders
• • 3. Right-handed
• • 4. Voluntarily join the study and sign the informed consent.
• Exclusion Criteria:
• • 1. Suicidal thoughts and behaviors
• • 2. serious physical disease
• • 3. diseases of the nervous system or other mental diseases
• • 4. Contraindications for MRI examination
• • 5. During pregnancy or lactation
• • 6. Allergy to narcotic drugs
• • 7. Contraindications with stellate ganglion block